Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

ClinicalTrials.gov ID: NCT01210495

Public ClinicalTrials.gov record NCT01210495. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 4:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A MULTICENTER, GLOBAL, RANDOMIZED, DOUBLE-BLIND STUDY OF AXITINIB PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA FOLLOWING FAILURE OF ONE PRIOR ANTIANGIOGENIC THERAPY

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma.

Study identification

NCT ID
NCT01210495
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
224 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 5, 2010
Primary completion
Mar 2, 2014
Completion
Dec 19, 2016
Last update posted
Jan 8, 2019

2010 – 2016

United States locations

U.S. sites
13
U.S. states
6
U.S. cities
10
Facility City State ZIP Site status
Alta Bates Summit Comprehensive Cancer Center Berkeley California 94704
UCSD Medical Center- La Jolla La Jolla California 92037
Moores UCSD Cancer Center La Jolla California 92093
University of California Irvine Medical Center Orange California 92868
UCSD Medical Center- Hillcrest San Diego California 92103
Florida Hospital Transplant Center, Liver Unit Orlando Florida 32804
Moffitt Cancer Center & Research Institute Tampa Florida 33612
University of Michigan Ann Arbor Michigan 48109
Nebraska Methodist Hospital Omaha Nebraska 68114
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 86169
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89119
Hospital of the University of Pennsylvania Philadelphia Pennsylvania 19104
Penn Presbyterian Medical Center Philadelphia Pennsylvania 19104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01210495, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 8, 2019 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01210495 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →